Research Analysts Offer Predictions for BioCryst Pharmaceuticals, Inc.’s FY2028 Earnings (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Analysts at HC Wainwright reduced their FY2028 earnings per share estimates for BioCryst Pharmaceuticals in a report released on Tuesday, May 7th. HC Wainwright analyst A. Fein now expects that the biotechnology company will earn $1.31 per share for the year, down from their prior forecast of $1.32. HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.69) per share.

A number of other brokerages also recently weighed in on BCRX. Needham & Company LLC reiterated a “buy” rating and set a $12.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday. JMP Securities increased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “market outperform” rating in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.

BioCryst Pharmaceuticals Trading Down 0.2 %

Shares of BioCryst Pharmaceuticals stock opened at $5.26 on Wednesday. The business has a 50-day moving average price of $4.90 and a two-hundred day moving average price of $5.45. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $8.96. The company has a market cap of $1.09 billion, a P/E ratio of -4.46 and a beta of 1.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The company had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. During the same quarter in the previous year, the company earned ($0.28) earnings per share. The business’s revenue for the quarter was up 34.9% on a year-over-year basis.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in BCRX. Fifth Third Bancorp lifted its position in BioCryst Pharmaceuticals by 17,500.0% in the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 3,500 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in BioCryst Pharmaceuticals by 96.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 2,388 shares in the last quarter. Quarry LP bought a new position in BioCryst Pharmaceuticals in the 4th quarter valued at about $54,000. Tower Research Capital LLC TRC lifted its position in BioCryst Pharmaceuticals by 131.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 5,912 shares in the last quarter. Finally, JGP Global Gestao de Recursos Ltda. bought a new position in BioCryst Pharmaceuticals in the 4th quarter valued at about $64,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.